Registration number: 11982070

Hyat Pharma Ltd

Contents

Company Information	1
Balance Sheet	2 to 3
Notes to the Unaudited Financial Statements	4 to 11

Hyat Pharma Ltd

Company Information

Directors

Mr Naser Mustafa El-Zebdeh Mrs Amal Bashir El-Zebdeh

Registered office

292 Crofton Road Orpington England BR6 8EY

Accountants

Alison & Ryan Robinson 22A Bank Street Ashford Kent TN23 1BE

Hyat Pharma Ltd

(Registration number: 11982070)
Balance Sheet as at 31 May 2026

	Note	2026 £	2025 £
Fixed assets
Intangible assets	4	792,917	847,917
Tangible assets	5	1,261	2,069
		794,178	849,986
Current assets
Stocks	6	65,976	62,798
Debtors	7	225,926	302,013
Cash at bank and in hand		82,176	80,173
		374,078	444,984
Creditors: Amounts falling due within one year	8	(551,113)	(633,828)
Net current liabilities		(177,035)	(188,844)
Total assets less current liabilities		617,143	661,142
Creditors: Amounts falling due after more than one year	8	(492,552)	(562,871)
Net assets		124,591	98,271
Capital and reserves
Called up share capital	9	200	200
Retained earnings		124,391	98,071
Shareholders' funds		124,591	98,271

For the financial year ending 31 May 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

•	The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
•	The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 7 September 2026 and signed on its behalf by:
 

Hyat Pharma Ltd

(Registration number: 11982070)
Balance Sheet as at 31 May 2026

......................................... Mr Naser Mustafa El-Zebdeh Director

Hyat Pharma Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 May 2026

1	General information

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
292 Crofton Road
Orpington
BR6 8EY
England

These financial statements were authorised for issue by the Board on 7 September 2026.

2	Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Hyat Pharma Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 May 2026

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class	Depreciation method and rate
Office equipment	25% straight line

Goodwill

Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the company’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is held in the currency of the acquired entity and revalued to the closing rate at each reporting period date. Goodwill is amortised over its useful life, which shall not exceed ten years if a reliable estimate of the useful life cannot be made.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class	Amortisation method and rate
Goodwill	5% straight line

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Hyat Pharma Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 May 2026

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

3	Staff numbers

The average number of persons employed by the company (including directors) during the year, was 11 (2025 - 10).

Hyat Pharma Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 May 2026

4	Intangible assets

	Goodwill  £	Total £
Cost or valuation
At 1 June 2025	1,100,000	1,100,000
At 31 May 2026	1,100,000	1,100,000
Amortisation
At 1 June 2025	252,083	252,083
Amortisation charge	55,000	55,000
At 31 May 2026	307,083	307,083
Carrying amount
At 31 May 2026	792,917	792,917
At 31 May 2025	847,917	847,917

5	Tangible assets

	Office equipment £	Total £
Cost or valuation
At 1 June 2025	4,478	4,478
At 31 May 2026	4,478	4,478
Depreciation
At 1 June 2025	2,409	2,409
Charge for the year	808	808
At 31 May 2026	3,217	3,217
Carrying amount
At 31 May 2026	1,261	1,261
At 31 May 2025	2,069	2,069

6

Stocks

	2026 £	2025 £
Other inventories	65,976	62,798

Hyat Pharma Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 May 2026

7

Debtors

Current	2026 £	2025 £
Trade debtors	1,446	(941)
Prepayments	1,745	1,745
Other debtors	222,735	301,209
	225,926	302,013

Hyat Pharma Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 May 2026

8

Creditors

Creditors: amounts falling due within one year

	Note	2026 £	2025 £
Due within one year
Loans and borrowings	10	90,360	95,810
Trade creditors		180,646	73,562
Taxation and social security		57,861	51,592
Accruals and deferred income		5,770	5,770
Other creditors		216,476	407,094
		551,113	633,828

Creditors: amounts falling due after more than one year

	Note	2026 £	2025 £
Due after one year
Loans and borrowings	10	492,552	562,871

9	Share capital

Allotted, called up and fully paid shares

	2026		2025
	No.	£	No.	£
Ordinary A of £1 each	-	-	-	-
Ordinary B of £1 each	-	-	-	-
Ordinary C of £1 each	200	200	200	200
Ordinary of £0 each	-	-	-	-
	200	200	200	200

10	Loans and borrowings

Non-current loans and borrowings

	2026 £	2025 £
Bank borrowings	492,552	562,871

Hyat Pharma Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 May 2026

Current loans and borrowings

	2026 £	2025 £
Bank borrowings	90,360	95,810

Bank borrowings

Business loan is denominated in Sterling with a nominal interest rate of 3.4%%, and the final instalment is due on 30 November 2035. The carrying amount at year end is £Nil (2025 - £Nil).

Business loan is denominated in Sterling with a nominal interest rate of 3.4%%, and the final instalment is due on 30 November 2025. The carrying amount at year end is £Nil (2025 - £Nil).

11

Dividends

Interim dividends paid

		2026 £		2025 £
Interim dividend of £325.50 (2025 - £295.00) per each Ordinary C		65,100		59,000

12	Related party transactions

Transactions with directors

2026	At 1 June 2025 £	Advances to director £	At 31 May 2026 £
Mr Naser Mustafa El-Zebdeh
Director loan to the company	473	(435)	38
Mrs Amal Bashir El-Zebdeh
Director loan to the company	270,796	(54,000)	216,796

Hyat Pharma Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 May 2026

2025	At 1 June 2024 £	Repayments by director £	At 31 May 2025 £
Mr Naser Mustafa El-Zebdeh
Director loan to the company	54	419	473
Mrs Amal Bashir El-Zebdeh
Director loan to the company	269,946	850	270,796

Directors' remuneration

The directors' remuneration for the year was as follows:

	2026 £	2025 £
Remuneration	12,570	12,570